A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

Inclusion Criteria

• •1. That the patient was over the age of 18 when the sample was taken/consented to.
• •2. Availability of patient informed consent or non-opposition form to perform exploratory research matching at least one of the MOSAIC objectives (unless authorisation is granted by the local Institutional Review Board / Independent Ethics Committee (IRB/IEC) for the use of samples in the study according to local regulations and law).
• •3. Have a confirmed diagnosis based on international criteria for the relevant tumor type.
• •4. Confirmed formalin fixed and paraffin embedded (FFPE) tissue availability to generate at least the 3 core data modalities, and preferentially all MOSAIC data modalities.
• •5. Confirmed availability of associated clinical data.
• •6. Qualification of the paraffin tissue block meeting all of the following:
• •* Being of the expected tumor type
• •* For solid tumors (all cancer indications except diffuse large B cell lymphoma (DLBCL)): Tumor cell content ranging from 40% to 80% on an hematoxylin and eosin (H\&E) section within a specified area as dictated by the lab protocol specific to the technique utilized
• •* For DLBCL, a minimum of 80% of high grade component on an H\&E section within a specified area as dictated by the lab protocol specific to the technique utilized
• •* Wherever possible, the remaining tissue thickness must be over 125 micrometers (indicative range)
• •* Tumor sample must be \<10 years old